To analyze the association between non-alcoholic fatty liver disease (NAFLD) and the incidence of diabetic nephropathy in patients with type 2 diabetes, the incidence of diabetic nephropathy was assessed in 413 type 2 diabetic patients, by testing the 24 h urinary albumin excretion rate (UAER). The NAFLD was diagnosed based on patient’s medical history and liver ultrasound. The difference in diabetic nephropathy incidence between patients with and without NAFLD was tested by χ 2. Multivariate logistic regression analysis was used to assess the factors associated with diabetic nephropathy among type 2 diabetic patients. Total 363 out of 413 type 2 diabetic patients were enrolled in this study. The incidences of NAFLD and diabetic nephropathy in participants were approximately 56% (202/363) and 38% (137/363) respectively, and there was no significant difference in the prevalence of diabetic nephropathy between patients with and without NAFLD (37.1% vs. 38.5%, p = 0.787). The duration of diabetes (odds ratio [OR] 1.065, 95% confidence interval [CI] 1.014–1.120, p = 0.012), waist circumference (OR 1.077, 95% CI 1.040–1.116, p = 0.000), and fasting blood glucose (FBG; OR 1.136, 95% CI 1.023–1.1262, p = 0.017) were significantly associated with diabetic nephropathy, whereas sex, high blood pressure, total cholesterol (TC), triglyceride (TG), and ankle brachial pressure index (ABI) were not significantly associated with the disorder. The present results suggest that NAFLD is not related to the incidence of diabetic nephropathy in type 2 diabetes, but the duration of diabetes, waist circumference, and FBG are important factors for diabetic nephropathy in type 2 diabetes.
Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med 2002, 346, 1221–1231.
[3]
McCullough, A.J. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol 2006, 40, S17–S29.
[4]
Starley, B.Q.; Calcagno, C.J.; Harrison, S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51, 1820–1832.
[5]
Targher, G.; Bertolini, L.; Poli, F.; Rodella, S.; Scala, L.; Tessari, R.; Zenari, L.; Falezza, G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54, 3541–3546.
[6]
Targher, G.; Bertolini, L.; Rodella, S.; Tessari, R.; Zenari, L.; Lippi, G.; Arcaro, G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30, 2119–2121.
[7]
Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Tessari, R.; Zenari, L.; Day, C.; Arcaro, G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, 1212–1218.
[8]
Shibata, M.; Kihara, Y.; Taguchi, M.; Tashiro, M.; Otsuki, M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30, 2940–2944.
[9]
Adams, L.A.; Waters, O.R.; Knuiman, M.W.; Elliott, R.R.; Olynyk, J.K. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am. J. Gastroenterol 2009, 104, 861–867.
[10]
Targher, G.; Chonchol, M.; Zoppini, G.; Abaterusso, C.; Bonora, E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? J. Hepatol 2011, 54, 1020–1029.
[11]
Fugmann, T.; Borgia, B.; Révész, C.; Godó, M.; Forsblom, C.; Hamar, P.; Holth？fer, H.; Neri, D.; Roesli, C. Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Kidney Int 2011, 80, 272–281.
[12]
Leit？o, C.B.; Canani, L.H.; Bolson, P.B.; Molon, M.P.; Silveiro, S.P.; Gross, J.L. What values should be used to diagnose microalbuminuria in patients with diabetes mellitus? Arq. Bras. Endocrinol. Metabol 2006, 50, 322–326.
[13]
Levin-Iaina, N.; Iaina, A.; Raz, I. The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab. Res. Rev 2011, 27, 235–243.
[14]
Kumar, R.; Winocour, P.H. Dual blockade of the rennin-angiotensin system in diabetes—Rationale and risks. Br. J. Diabetes Vasc. Dis 2005, 5, 266–271.
[15]
Medina, J.; Fernandez-Salazar, L.I.; Garcia-Buey, L.; Moreno-Otero, R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004, 27, 2057–2066.
[16]
Targher, G.; Bertolini, L.; Rodella, S.; Zoppini, G.; Lippi, G.; Day, C.; Muggeo, M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51, 444–450.
[17]
Hwang, S.T.; Cho, Y.K.; Yun, J.W.; Park, J.H.; Kim, H.J.; Park, D.I.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Rhee, E.J.; et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern. Med. J 2010, 40, 437–442.
[18]
Manco, M.; Ciampalini, P.; deVito, R.; Vania, A.; Cappa, M.; Nobili, V. Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatr. Nephrol 2009, 24, 1211–1217.
[19]
Bloomgarden, Z.T. Diabetic Nephropathy. Diabetes Care 2005, 28, 745–751.
[20]
Lakhotia, M.; Gehlot, R.S.; Jain, P.; Sharma, S.; Singh, M. Lipoprotein(a) in Type 2 Diabetic Subjects in relation to Diabetic Microvascular Complications. JIACM 2003, 4, 304–307.
[21]
Farrell, G.C.; Chitturi, S.; Au, G.K.; Sollano, J.D. Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol 2007, 22, 775–777.
[22]
Zeng, M.D.; Li, Y.M.; Chen, C.W.; Lu, L.G.; Fan, J.G.; Wang, B.Y.; Mao, Y.M. Guidelines for the diagnosis and treatment of alcoholic liver disease. J. Dig. Dis 2008, 9, 113–116.
